Search
for

    Glossary

    Similar Terms

    Learn

    3 / 3 results

      learn Clascoterone

      a novel topical treatment that inhibits DHT on androgen receptors

      learn KY19382

      compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles

    Research

    5 / 58 results

    Community Join

    5 / 101 results

      community Brief update clascoterone phase 3 - Breezula

      in Research/Science  4 upvotes 9 months ago
      Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

      community BREEZULA COVID UPDATE: Filing for Special Protocol Assessment with FDA

      in Research/Science  61 upvotes 4 years ago
      The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

      community Disappointing news on Breezula/CB-03-01

       22 upvotes 5 years ago
      The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

      community New Latanoprost-Based Formula Used by Hollywood Celebrities

      in Treatment  26 upvotes 1 year ago
      A new Latanoprost-based formula used by Hollywood celebrities to treat hair loss, with the formula containing minoxidil, tretinoin, melatonin, azelaic acid, zinc thymulin, vitamin B6, sandalore and methyl vanillate. It also mentions the potential of offering a combined sublingual minoxidil/oral dutasteride option in the future.